Can this be done 8 pm 4/22

profileSaltwata2012
Sociodemographicstuff.pdf

1Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

Effect of socio-demographic factors on the association between multimorbidity and healthcare costs: a population- based, retrospective cohort study

Kednapa Thavorn,1,2,3 Colleen J Maxwell,3,4 Andrea Gruneir,3,5,6,7 Susan E Bronskill,3,5 YuQing Bai,3 Anna J Koné Pefoyo,8,9 Yelena Petrosyan,1,5 Walter P Wodchis3,5,10

To cite: Thavorn K, Maxwell CJ, Gruneir A, et al. Effect of socio-demographic factors on the association between multimorbidity and healthcare costs: a population-based, retrospective cohort study. BMJ Open 2017;7:e017264. doi:10.1136/ bmjopen-2017-017264

► Prepublication history and additional material for this paper are available online. To view, please visit the journal (http:// dx. doi. org/ 10. 1136/ bmjopen- 2017- 017264).

Received 11 April 2017 Revised 3 August 2017 Accepted 11 August 2017

For numbered affiliations see end of article.

Correspondence to Dr Walter P Wodchis; walter. wodchis@ utoronto. ca

Research

AbstrACt Objectives To estimate the attributable costs of multimorbidity and assess whether the association between the level of multimorbidity and health system costs varies by socio-demographic factors in young (<65 years) and older (≥65 years) adults living in Ontario, Canada. Design A population-based, retrospective cohort study setting The province of Ontario, Canada Participants 6 639 089 Ontarians who were diagnosed with at least one of 16 selected medical conditions on 1 April 2009. Main outcome measures From the perspective of the publicly funded healthcare system, total annual healthcare costs were derived from linked provincial health administrative databases using a person-level costing method. We used generalised linear models to examine the association between the level of multimorbidity and healthcare costs and the extent to which socio- demographic variables modified this association. results Attributable total costs of multimorbidity ranged from C$377 to C$2073 for young individuals and C$1026 to C$3831 for older adults. The association between the degree of multimorbidity and healthcare costs was significantly modified by age (p<0.001), sex (p<0.001) and neighbourhood income (p<0.001) in both age groups, and the positive association between healthcare costs and levels of multimorbidity was statistically stronger for older than younger adults. For individuals aged 65 years or younger, the increase in healthcare costs was more gradual in women than in their male counterparts, however, for those aged 65 years or older, the increase in healthcare costs was significantly greater among women than men. Lastly, we also observed that the positive association between the level of multimorbidity and healthcare costs was significantly greater at higher levels of marginalisation. Conclusion Socio-demographic factors are important effect modifiers of the relationship between multimorbidity and healthcare costs and should therefore be considered in any discussion of the implementation of healthcare policies and the organisation of healthcare services aimed at controlling healthcare costs associated with multimorbidity.

bACkgrOunD Multimorbidity, the presence of two or more coexisting conditions within a single person, is increasingly prevalent due to advances in life-extending medical treatments and increases in life expectancy.1 2 Internationally, the prevalence of multimorbidity has been shown to range from 17% in young adults3 to 82% in older adults living in nursing homes.4 In the province of Ontario, Canada, the prev- alence of multimorbidity based on 16 selected conditions rose from 17.4% in 2003 to 24.3% in 2009, and this increase was evident across all age groups.5

Higher levels of multimorbidity are asso- ciated with impaired physical functioning,6

strengths and limitations of this study

► This population-based study was based on a large sample size and used robust costing and generalised linear model regression techniques.

► The availability of linked and patient-level health administrative databases allows the estimation of the total health system costs associated with multimorbidity from all healthcare sectors.

► The use of health administrative databases can also minimise potential recall and non-response biases that are commonly found in survey data.

► The total healthcare costs reported in this study may be underestimated because they were derived based on 16 selected medical conditions. Moreover, it was not possible to measure certain costs (eg, deductibles and copayments borne by supplemental health insurance, out-of-pocket beneficiary payments and indirect costs associated with caregiving) with our data.

► The study did not take into account particular clusters of medical conditions. It is possible that the relationship between multimorbidity and healthcare costs may vary according to the types and patterns of comorbid medical conditions.

2 Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

poorer quality of life,7 more frequent use of health services and higher risk of death.8 In addition, individ- uals with multimorbidity may experience faster disease progression and require more complex medical care.9 Consequently, these individuals may be at a higher risk of receiving suboptimal care,10 inappropriate prescrip- tions11 and experiencing potentially preventable hospital- isations.12 These adverse health outcomes can impose a substantial burden on patients, family caregivers and the healthcare system.

The relationship between multimorbidity and health- care costs is well-documented and has been shown to be curvilinear or exponential across jurisdictions. The average Medicare payments in the USA ranged from US$1154 among part A and part B beneficiaries with one chronic condition to US$13 973 among beneficiaries with at least four chronic conditions (a 12-fold difference).12 Similarly, the mean total health system costs among older adults with multimorbidity in Switzerland were nearly six times higher than among those without multimorbidity.13

Despite an abundance of research describing the rela- tionship between multimorbidity and healthcare costs, existing studies have some important methodological and conceptual limitations. Some previous studies14 15 used ordinary least squares (OLS) regression despite the fact that the positively skewed distribution of cost data often violates the normality assumption of OLS.16 Others attempted to overcome this problem by transforming cost data to the logarithmic scale13 17; however, this trans- formation may still result in interpretation problems, as regression on transformed costs provides the predic- tion of a median instead of the arithmetic mean costs.18 Importantly, the role of socio-demographic characteris- tics as effect modifiers of the relationship between multi- morbidity and healthcare costs remains poorly described, although previous research has shown that the specific types of disease clusters vary by age and sex2 19 and that multimorbidity is more prominent in selected visible minority and low-socioeconomic status populations.20

The objectives of this study were, therefore, to estimate the health system costs attributable to multimorbidity using a more rigorous and appropriate approach, and to assess the extent to which the relationship between the level of multimorbidity and health system costs varies according to socio-demographic characteristics.

MethODs study design and sample This population-based, retrospective cohort study included all residents of the province of Ontario between 1 April 2001 and 31 March 2010, who were enrolled in the Ontario Health Insurance Plan (OHIP), and were diagnosed with at least one of the following selected 16 medical conditions between 1 April 2001 and 31 March 2009 (study index date): acute myocardial infarction (AMI), arthritis, asthma, cancer, cardiac arrhythmia, chronic coronary syndrome, chronic obstructive

pulmonary disorder (COPD), congestive heart failure, dementia, depression, diabetes, hypertension, osteopo- rosis, renal failure, rheumatoid arthritis and stroke. These conditions were selected because previous research and clinical experts agreed that they were highly prevalent and represented a substantial care and economic burden for Canada’s healthcare system.5 21 We excluded indi- viduals if they met the following criteria: had an invalid health card number, were older than 105 years, died or moved out of the province prior to the index date. Indi- viduals with no contact with the healthcare system within the past 5 years prior to the index date were also excluded (excepting infants), as they may have left the province or experienced an unreported death.

Data sources We linked multiple provincial health administrative data- bases anonymously using unique encrypted identifiers. The Discharge Abstract Database provides data for all hospital discharges in Ontario, and the OHIP claims database includes billing claims for all physician encoun- ters. We used the Registered Persons Database to iden- tify Ontarians who were eligible for health insurance coverage and derive their age. The linked database was housed and secured at the Institute for Clinical Evaluative Sciences (ICES) under data security and privacy policies and procedures approved by the Information and Privacy Commissioner of Ontario. This study was approved by the Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Each medical condition was defined using diagnostic algorithms and consultation codes that have been vali- dated or used in previous studies. We defined six condi- tions (AMI, asthma, chronic heart failure, COPD, diabetes and hypertension) based on validated population-derived registries held at ICES.22–28 These conditions were all defined based on one diagnosis recorded in acute care or two diagnoses recorded in ambulatory care (physician) records within a 2-year period (ie, between 2007/2008 and 2008/2009), except for AMI, which was defined using acute care records in 2008/2009. A similar approach was adopted to define the remaining medical conditions including arthritis, cancer, cardiac arrhythmia, chronic coronary syndrome, dementia, depression, osteoporosis, renal failure, rheumatoid arthritis and stroke. A list of diagnostic codes used to define these medical conditions are shown in online supplementary appendix 1.

Measures Healthcare costs Healthcare costs were estimated from the perspective of the publicly funded healthcare system; accordingly, only direct costs borne to the Ontario Ministry of Health and Long-Term Care were considered. In Ontario, medically necessary hospital and physician services are paid for by the publicly financed health insurance plan; however, public coverage for prescription drugs is primarily limited to residents aged 65 years and over, social assistance

3Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

recipients as well as those with high prescription drug costs compared with their net household income.

We identified, measured and valued direct healthcare costs by applying a person-level costing technique that was developed and validated based on the Ontario health administrative data.29 We calculated the costs of inpatient hospitalisations, emergency department visits, same day surgeries and inpatient rehabilitation by multiplying the weighted volume of services by the average provincial costs per weighted case. We obtained the costs of fee-for-ser- vice physician and outpatient diagnostic or laboratory services through OHIP fee approved as outlined in the Ontario Health Insurance Schedule of Benefits and Fees.30 Non-fee-for-service physician payments were calcu- lated by applying applicable capitation payments or the median amount reimbursed for the same service code for the specific fiscal year.29 Costs for high-cost medical device equipment were estimated from the amount reimbursed to patients recorded in the Assistive Devices Program database. Complex continuing care and inpa- tient psychiatric costs were based on case mix, number of days in care and resource utilisation groups.31 Patient costs for long-term care were estimated based on a fixed per diem according to prevailing government payment rates, and costs for home care were estimated using the average cost per hour. We used pharmacy payments recorded in the Ontario Drug Benefit database to capture prescription medication costs for individuals eligible for public coverage. Annual total direct healthcare costs were the sum of costs across healthcare sectors for each patient for a 1-year period after the study index date, that is, from April 2009 to March 2010.

We categorised healthcare costs into five components: physician, hospital, drug, continuing care and other healthcare delivery costs. Physician costs included profes- sional fees paid by the provincial insurance plan directly to physicians in private practice. Hospital costs included amounts paid to healthcare institutions, including those providing acute care, extended and chronic care, rehabil- itation and convalescent care, psychiatric care as well as drugs dispensed in hospitals. Drug costs consisted of the costs of prescriptions dispensed at outpatient pharma- cies to individuals eligible for provincial coverage while continuing care costs included expenditure on home care and residential long-term (nursing-home) care. The other healthcare delivery costs category represented expenditures on an assistive device programme that subsi- dises high-cost equipment, such as wheel chairs, walkers, continuous positive airway pressure devices and insulin pumps, for patients with physical disabilities. All costs were expressed in 2009 Canadian Dollars (C$).

Independent variables Multimorbidity was defined as the occurrence of two or more chronic diseases among the 16 selected conditions within a single individual and was categorised into five groups. A categorical variable was created to capture those with no multimorbidity (single disease only), two,

three, four and five or more multimorbid conditions. Socio-demographic variables included age, sex, income and level of marginalisation. As prescription drug costs among Ontarians aged <65 years were primarily covered by private drug plans, we ran separate regressions for younger (<65 years) and older (65+ years) cohorts, and also included a continuous variable for age in the models. Income level was categorised into five quintiles, with the lowest quintile reflecting the lowest income level. We used the Ontario Marginalisation Index, a validated census- based and geographically based index, as a proxy for individual-level socio-demographic factors.32 The index consisted of four dimensions of marginalisation: mate- rial deprivation; residential instability; ethnic concentra- tion and dependency. Lower scores on each dimension represent areas that are the least marginalised and higher scores represent areas that are the most marginalised. This index has been shown to be associated with several health outcomes.33

We also controlled for other factors that may confound the impact of multimorbidity on healthcare costs, such as the type of primary care model and geographic location. Selection of such factors was guided by previous health- care cost studies12 34 35 and was subject to the availability of data on these factors in Ontario administrative data- bases. The payment scheme of primary care services was categorised into three groups: group-based teams with capitation/salary and team-based payment (family health teams/other group models); capitation or blended payment models (family health networks/family health organisations) or primarily fee for service (family health groups and non-rostered patients). Lastly, we assigned a geographic location to each individual using the Rurality Index for Ontario,36 whereby a value >40 was considered to be a designated rural area.

Analysis Annual healthcare costs per capita were described by health service sector, age group (<65 vs ≥65 years), the degree of multimorbidity and each of the independent factors, such as sex, age group and level of marginalisa- tion. Multivariate regression analyses were used to assess the incremental costs of interest in this study. To iden- tify the regression model that best fits the cost data, we followed the steps suggested by Manning and Mullahy.37 We first ran OLS of the logarithmic transformation of cost data on the number of medical conditions and other confounding factors; however, the OLS regression was deemed inappropriate because the residuals were not normally distributed. Therefore, the generalised linear model (GLM) with a log-link function and a gamma distri- bution was chosen because a modified Park test suggested that the variance was proportional to the conditional mean. The GLM allows us to estimate mean healthcare costs without the need for retransformation.

Attributable costs due to multimorbidity were esti- mated by subtracting the mean predicted cost of one medical condition from the mean predicted cost of two

4 Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

conditions, two from three conditions, three from four conditions and four from at least five conditions, respec- tively. To investigate whether the relationship between the level of multimorbidity and healthcare costs was moderated by socio-demographic factors, we added two-way interaction terms between the level of multimor- bidity and each socio-demographic factor, including sex, age, income level, deprivation quintile, instability quin- tile, dependency quintile and ethnic concentration quin- tile. The significance of interaction terms was assessed by comparing the likelihood ratio of the full model with all interaction terms with the model without interaction terms using the likelihood ratio test.

The model performance, including goodness of fit and specifications, was examined by checking the scaled deviance, Pearson’s χ2 statistics and residual plots, respec- tively. All analyses were performed using SAS statistical software for UNIX (V.9.3; SAS Institute, Cary, North Carolina, USA).

results We identified a cohort of 6 639 089 individuals living with at least one of the selected 16 medical conditions in Ontario in 2009 (see online supplementary appendix 2 for baseline characteristics). Our cohort represents about 50% of the total population in the province of Ontario in 2009. Close to half of the study cohort (48%) had at least two selected medical conditions, and this prevalence was found to increase with age. The majority of the study cohort was younger than 65 years of age (75%) and just over half was female (53%). Nearly all individuals (91%) resided in non-rural areas, and about one-third (33%) lived in neighbourhoods with a high proportion of diverse ethnic groups.

The total annual healthcare cost estimated for the study cohort was C$26.5 billion. As shown in figure 1, individuals living with at least two selected medical conditions represented 24.4% of the total population of Ontario (~13 million) but accounted for approximately two-thirds (67.9%) of total allocatable healthcare costs in 2009/2010. By contrast, individuals without multimor- bidity who accounted for 76% of the total population were responsible for only 32.1% of total allocatable healthcare costs. On average, annual total costs per capita amounted to C$2217 in individuals <65 years and C$9398 in those aged 65 years or older.

Table 1 shows the annual total costs per capita by base- line characteristics for young and older adults. For both age groups, per capita total healthcare costs were higher in women than in men. The average healthcare costs increased with older age, and greater levels of marginali- sation were associated with higher healthcare costs in both age groups. Mean total healthcare costs were the highest among individuals living in the most deprived and most unstable areas as well as those who were highly depen- dent; however, mean total costs decreased as income level increased.

Figure 2 illustrates the distribution of total cost per capita by type of services. Among individuals <65 years, hospitalisation was the primary cost driver and respon- sible for 47% of total healthcare costs, followed by physi- cian costs (32%), drug costs (10%) and continuing care costs (6%). For older adults, hospital costs remained the largest cost component (41%), followed by continuing care costs (23%), drug costs (19%) and physician costs (15%). Figure 2 also reveals that unadjusted mean total costs increased with additional numbers of medical conditions, ranging from C$1352 in individuals <65 years without multimorbidity to C$13 105 in those living with

Figure 1 Distribution of total number of population and total health system costs in Ontario from 1 April 2009 to 31 March 2010.

5Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

Table 1 Annual per capita healthcare costs by baseline characteristics and age group, 1 April 2009 to 31 March 2010

<65 years (n=5 004 699)

≥65 years (n=1 634 390)

N

Per capita healthcare cost (C$)

N

Per capita healthcare cost (C$)

Mean (SD) Median (IQR) Mean (SD) Median (IQR)

All cohort 5 004 699 2217 (9630)

502 (193–1317)

1 634 390 9398 (19 796)

2982 (1448–7178)

Sex

Female 2 618 591 2311 (9044)

624 (248–1546)

923 053 9526.96 (19 245)

2991.97 (1461–7344)

Male 2 386 108 2113 (10 233)

378.67 (132–1058)

711 337 9230.31 (20 488)

2968.13 (1431–6982)

Age group (years)

<20 809 782 997 (6420)

257 (103–600)

20–44 1 784 314 1835 (7997)

440 (155–1171)

45–64 3 247 243 2910 (11 414)

684 (291–1725)

65–74 1 219 877 6424 (16 464)

2363 (1173–4757)

75+ 797 750 12 517 (22 351)

3964 (1884–12 277)

Income quintile

Lowest 935 048 2822 (11 333)

580 (206–1699)

314 616 10 646 (21 501)

3325 (1596–8667)

Middle-low 970 797 2360 (10 276)

521 (199–1380)

336 928 9529 (20 218)

3053 (1501–7296)

Middle 999 087 2107 (9146)

498 (195–1268)

318 557 9319 (19 552)

2992 (1470–7114)

Middle-high 1 042 284 2008 (8 899)

487 (195–1226)

322 798 9120 (19 279)

2916 (1426–6873)

Highest 1 009 890 1903 (8391)

475 (192–1180)

331 022 8549 (18 309)

2747 (1351–6352)

Rurality index

Non-rural 4 579 691 2206 (9 605)

509 (197–1320)

1 459 014 9448 (19 998)

3005 (1470–7161)

Rural 356 361 2522 (10 112)

501 (197–1441)

157 864 9333 (18 303)

2918 (1400–7798)

Deprivation quintile

Least deprived 1 282 898 1894.17 (8 596 59)

476 (193–1170)

371 547 9167 (19 628)

2823 (1380–6709)

Less deprived 1 136 731 2015 (8 810)

489 (196–1231)

368 124 8935 (18 928)

2898 (1423–6759)

Somewhat deprived

982 133 2193 (9 240)

504 (196–1311)

346 326 9165 (19 300)

2978 (1463–7030)

Very deprived 808 152 2438 (10 281)

511 (200–1443)

293 434 9541 (19 951)

3100 (1520–7467)

Most deprived 705 593 2941 (11 861)

600 (210–179)

228 501 10 517 (21 250)

3326 (1599–8570)

Instability quintile

Least dependent 1 211 734 2007 (8 674)

489 (188–1250)

188 787 8149 (19 413)

2713 (1307–5882)

Less dependent 1 179 936 2078 (9 134)

500 (195–1275)

276 819 8359 (18 652)

2777 (1353–6167)

Somewhat dependent

976 538 2230 (9 793)

506 (198–1320)

303 853 8717 (19 018)

2849 (1401–6548)

Very dependent 808 196 2349 (9 954)

515 (201–1375)

326 662 9068 (19 195)

2944 (1458–6958)

Continued

6 Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

five or more medical conditions, corresponding to a 10-fold increase. On the other hand, while C$4185 was spent on older adults without multimorbidity, spending increased by about fivefold to C$19 196 in those living with five or more medical conditions.

Table 2 shows adjusted attributable costs of multimor- bidity after controlling for other factors. Among individ- uals <65 years, the attributable total cost was C$377 in those living with two medical conditions and C$2073 in those living with at least five medical conditions, corre- sponding to a sixfold increase in attributable cost. Simi- larly, attributable total costs in older adults also rose with increasing number of medical conditions, ranging from

C$1026 in those with two medical conditions to C$3831 in those with five or more. The magnitude of an incre- mental cost, however, depended on the reference cate- gory. Specifically, one additional medical condition in young adults without multimorbidity led to an attribut- able cost of C$377, while for young adults who already had three medical conditions, one additional health condition resulted in a total cost of C$798. These incre- mental costs were even greater in older adults, among whom the incremental cost rose from C$1026 (one vs two conditions) to C$1652 (three vs four conditions). Similar patterns were observed for subdivided healthcare costs, which varied across age groups (table 2). An additional

<65 years (n=5 004 699)

≥65 years (n=1 634 390)

N

Per capita healthcare cost (C$)

N

Per capita healthcare cost (C$)

Mean (SD) Median (IQR) Mean (SD) Median (IQR)

Most dependent 739 103 2650 (10 947)

550 (213–1507)

511 811 10 961 (20 953)

3381 (1636–9336)

Ethnic concentration quintile

Lowest 564 476 2398 (9 766)

500 (200–1370)

283 980 9309 (18 529)

2983 (1463–7533)

Middle-low 756 120 2288 (9 552)

491 (196–1317)

304 526 9170 (18 773)

2969 (1458–7283)

Middle 854 573 2280 (9 780)

497 (196–1317)

305 524 9540 (19 678)

3011 (1478–7419)

Middle-high 1 028 876 2190 (9 565)

502 (195–1309)

294 164 9600 (20 240)

3012 (1473–7266)

Highest 1 711 462 2124 (9 468)

528 (199–1331)

419 738 9288 (20 751)

2981 (1441–6694)

Table 1 Continued

Figure 2 Unadjusted mean total healthcare cost per capita for Ontario adults, by service type, number of conditions and age group from 1 April 2009 to 31 March 2010.

7Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

medical condition caused a onefold to threefold increase in the costs of each health sector except for hospital care, for which incremental costs increased steadily from C$185 to C$802 in the younger cohort and C$232 to C$1060 in the older adult cohort.

We also found that the association between the number of medical conditions (ie, the degree of multimorbidity) and healthcare costs was significantly modified by age and sex for both young and older adults (table 3), and the positive association between healthcare costs and levels of multimorbidity was significantly stronger for older than younger adults. For individuals aged 65 years or younger, the increase in healthcare costs was more gradual in women than in their male counterparts, however, among those aged 65 years or older, the increase in healthcare costs in women was significantly greater than in men.

For both age groups, we observed small interaction effects between the number of medical conditions and other socio-demographic factors. The rise in healthcare costs as the level of multimorbidity increased was less pronounced among high-income individuals than low-in- come individuals, and the association between the level of multimorbidity and healthcare costs was significantly modified by the level of deprivation, instability, depen- dency and ethnic concentration. The positive association between the level of multimorbidity and healthcare costs was stronger among individuals living in more deprived, unstable, dependent or diverse ethnic groups than those living in less deprived, stable, dependent or high concen- tration of ethnic diversity areas. We did not observe a significant interaction between the number of medical conditions and the level of dependency in the older adult cohort.

DisCussiOn Individuals living with multimorbidity accounted for 79% of total healthcare costs incurred by our study cohort and 68% of total allocatable healthcare costs in Ontario in 2009. Although there is a growing body of literature docu- menting the economic burden of multimorbidity in other jurisdictions,12 13 38 the current study provides further evidence that the relatively small proportion of the popu- lation with multimorbid conditions is responsible for a disproportionately high percentage of total healthcare costs. Moreover, we observed this disproportionate rela- tionship in both young (<65 years) and (65+ years) older cohorts, suggesting that any approaches to containing the healthcare costs of multimorbidity should be imple- mented across all age groups.

Our study demonstrated that healthcare costs increased significantly with higher levels of multimorbidity, and that this positive association exists even after the adjust- ment for confounding factors and a skewed distribution of cost data using the generalised linear model with a log link function and a gamma distribution. The expo- nential relationship between multimorbidity and incre- mental healthcare costs shown in this study suggests that T

a b

le 2

A

d ju

st e d

in c re

m e n ta

l t o

ta l h

e a lt h c a re

c o

st s

b y

th e d

e g

re e o

f m

u lt im

o rb

id it y

a n d

a g

e g

ro u p

*, 1

 A p

ri l 2

0 0 9

t o

3 1

 M a rc

h 2

0 1

0

C o

n d

it io

n s

< 6 5 y

e a

rs (n

= 5  0

0 4  6

9 9 )

≥ 6 5 y

e a

rs (n

= 1  6

3 4  3

9 0 )

To ta

l ( C

$ )

P h

ys ic

ia n

(C

$ )

H o

s p

it a

l (C

$ )

D ru

g (C

$ )

C o

n ti

n u

in g

c

a re

( C

$ )

O th

e rs

(C $ )

To ta

l (C

$ )

P h

ys ic

ia n

(C $ )

H o

s p

it a

l (C

$ )

D ru

g (C

$ )

C o

n ti

n u

in g

c

a re

( C

$ )

O th

e rs

(C $

)

Tw o

v s

o n e

3 7 6 .5

0 2 0 0 .2

6 1 8 5 .1

2 2 3 2 .3

7 2 8 8 .7

1 2 3 .9

6 1 0 2 5 .7

6 1 6 6 .4

8 2

3 1

.6 0

3 5

0 .2

9 2

5 4

.1 4

2 3

.5 4

T h re

e v

s tw

o 5 3 4 .3

4 2 3 8 .2

8 2 0 7 .2

2 2 5 2 .8

4 2 0 7 .8

3 2 3 .8

1 1 2 7 9 .9

6 2 0 1 .2

0 2

4 7

.7 6

4 0

3 .5

6 3

1 4

.9 1

2 8

.5 1

F o

u r

vs

th re

e 7 9 8 .0

3 2 8 6 .2

9 2 6 4 .7

5 3 1 6 .4

3 2 3 4 .5

8 2 4 .6

7 1 6 5 1 .9

2 2 2 7 .0

4 3

5 3

.6 0

4 2

9 .0

1 3

6 7

.4 5

3 3

.1 7

≥ F

iv e v

s fo

u r

2 0 7 2 .5

7 5 1 5 .8

0 8 0 1 .6

4 6 6 6 .1

3 4 8 6 .5

8 3 7 .6

4 3 8 3 1 .4

0 4 0 0 .5

7 1

0 6

0 .0

0 6

7 3

.8 9

7 3

2 .1

9 6

3 .7

6

*A d

ju st

e d

f o

r se

x, a

g e , in

c o

m e q

u in

ti le

, p

ri m

a ry

c a re

m o

d e l,

ru ra

lit y

in d

e x,

d e p

ri va

ti o

n q

u in

ti le

, in

st a b

ili ty

q u in

ti le

, d

e p

e n d

e n c y

q u in

ti le

a n d

e th

n ic

c o

n c e n tr

a ti o

n q

u in

ti le

.

8 Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

Table 3 Generalised linear models results for total healthcare costs†

<65 years (n=5 004 699)

≥65 years (n=1 634 390)

Coefficient SE Coefficient SE

Intercept 1.6844*** 0.0007 1.6049*** 0.0034

Age 0.0023*** 0.0001 0.0053*** 0.0001

Sex

Male Reference Reference

Female 0.0628*** 0.0002 −0.0023*** 0.0006

Number of medical conditions

One condition Reference Reference

Two conditions 0.1092*** 0.0017 0.1068*** 0.0044

Three conditions 0.2189*** 0.0027 0.1860*** 0.0045

Four conditions 0.3312*** 0.0050 0.2563*** 0.0049

≥Five conditions 0.4203*** 0.0080 0.3772*** 0.0048

Income quintile

Lowest Reference Reference

Middle-low −0.0043*** 0.0005 −0.0019* 0.0010

Middle −0.0045*** 0.0005 0.00014 0.0012

Middle-high −0.0044*** 0.0006 0.0001 0.0012

Highest −0.0080*** 0.0006 −0.0045*** 0.0013

Deprivation quintile

Least deprived Reference Reference

Less deprived −0.0006* 0.0004 −0.0014*** 0.0008

Somewhat deprived −0.0008* 0.0004 −0.0020** 0.0009

Very deprived 0.0022*** 0.0005 −0.0009 0.0011

Most deprived 0.0135*** 0.0006 0.0044*** 0.0013

Instability quintile

Least unstable Reference Reference

Less unstable 0.0039*** 0.0005 −0.0019** 0.0009

Somewhat unstable 0.0073*** 0.0005 −0.0008 0.0009

Very unstable 0.0122*** 0.0005 0.0031*** 0.0009

Most unstable 0.0247*** 0.0005 0.0087*** 0.0010

Ethnic concentration quintile

Lowest Reference Reference

Middle-low 0.0002 0.0004 −0.0005 0.0009

Middle 0.0018*** 0.0004 0.0022 0.0009

Middle-high 0.0047*** 0.0004 −0.0007 0.0010

Highest 0.0066*** 0.0004 −0.0043*** 0.0009

Dependency quintile

Least dependent Reference Reference

Less dependent 0.0004 0.0004 0.0012** 0.0005

Somewhat dependent 0.0001 0.0004 0.0027*** 0.0005

Very dependent 0.0009** 0.0004 0.0030*** 0.0005

Most dependent 0.0020*** 0.0005 0.0100*** 0.0005

Number of medical conditions * sex

One condition* male Reference Reference

Continued

9Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

<65 years (n=5 004 699)

≥65 years (n=1 634 390)

Coefficient SE Coefficient SE

Two conditions * female −0.0171*** 0.0016 −0.0029*** 0.0007

Three conditions * female −0.0396*** 0.0011 −0.0022*** 0.0008

Four conditions * female −0.0549*** 0.0007 0.0001 0.0008

≥Five conditions * female −0.0659*** 0.0005 0.0030*** 0.0008

Number of medical conditions * age

One condition * age Reference Reference

Two conditions * age −0.0007*** 0.0016 −0.0006*** 0.0001

Three conditions * age −0.0014*** 0.0011 −0.0010*** 0.0001

Four conditions * age −0.0022*** 0.0007 −0.0014*** 0.0001

≥Five conditions * age −0.0023*** 0.0005 −0.0023*** 0.0001

Number of medical conditions * income quintile

One condition* lowest Reference Reference

Two conditions*middle-low −0.0016* 0.0009 −0.0025* 0.0013

Three conditions * middle-low −0.0011 0.0013 −0.0037** 0.0014

Four conditions* middle-low −0.0043** 0.0020 −0.0043** 0.0015

≥Five conditions* middle-low −0.0031 0.0027 −0.0046** 0.0014

Two conditions*middle −0.0020** 0.0010 −0.0032** 0.0015

Three conditions * middle −0.0030** 0.0014 −0.0051** 0.0015

Four conditions* middle −0.0053** 0.0023 −0.0055** 0.0017

≥Five conditions* middle −0.0028 0.0031 −0.0072*** 0.0016

Two conditions*middle-high −0.0024** 0.0011 −0.0031* 0.0016

Three conditions * middle-high −0.0032** 0.0016 −0.0052** 0.0016

Four conditions* middle-high −0.0067** 0.0025 −0.0081*** 0.0018

≥Five conditions* middle-high −0.0093** 0.0034 −0.0070*** 0.0018

Two conditions*highest −0.0015 0.0011 −0.0036** 0.0017

Three conditions *highest −0.0031* 0.0017 −0.0063*** 0.0018

Four conditions* highest −0.0096*** 0.0027 −0.0088*** 0.0019

Five conditions* highest −0.0099** 0.0038 −0.0095*** 0.0019

Number of medical conditions * deprivation quintile

One condition* lowest Reference Reference

Two conditions*middle-low 0.0024*** 0.0007 −0.0001 0.0011

Three conditions * middle-low 0.0038 *** 0.0010 −0.0015 0.0011

Four conditions* middle-low 0.0027 0.0017 −0.0016 0.0013

≥Five conditions* middle-low 0.0060** 0.0026 −0.0029** 0.0012

Two conditions*middle 0.0047*** 0.0007 −0.0002 0.0012

Three conditions * middle 0.0067*** 0.0010 −0.0018 0.0013

Four conditions* middle 0.0062*** 0.0017 −0.0045** 0.0014

≥Five conditions* middle 0.0109*** 0.0026 −0.0042** 0.0014

Two conditions*middle-high 0.0057*** 0.0009 −0.0012 0.0014

Three conditions * middle-high 0.0071*** 0.0014 −0.0031** 0.0015

Four conditions* middle-high 0.0074*** 0.0022 −0.0051** 0.0016

≥Five conditions* middle-high 0.0111*** 0.0032 −0.0079*** 0.0016

Two conditions*highest 0.0073*** 0.0011 −0.0028 0.0017

Table 3 Continued

Continued

10 Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

<65 years (n=5 004 699)

≥65 years (n=1 634 390)

Coefficient SE Coefficient SE

Three conditions *highest 0.0108*** 0.0016 −0.0052** 0.0018

Four conditions* highest 0.0114*** 0.0026 −0.0089*** 0.0019

≥Five conditions* highest 0.0119*** 0.0036 −0.0098*** 0.0019

Number of medical conditions * instability

One condition* lowest Reference Reference

Two conditions*middle-low −0.0012** 0.0007 0.0009 0.0011

Three conditions * middle-low −0.0007 0.0010 0.0020 0.0012

Four conditions* middle-low −0.0016 0.0017 0.0010 0.0013

≥Five conditions* middle-low −0.0013 0.0026 0.0022 0.0014

Two conditions*middle −0.0017** 0.0008 0.0037** 0.0014

Three conditions * middle −0.0012 0.0012 0.0010 0.0013

Four conditions* middle −0.0002 0.0019 0.0022 0.0014

≥Five conditions* middle 0.0025 0.0027 0.0037** 0.0014

Two conditions*middle-high −0.0003 0.0009 0.0022* 0.0012

Three conditions * middle-high 0.0006 0.0012 0.0019 0.0013

Four conditions* middle-high 0.0011 0.0019 0.0033** 0.0014

≥Five conditions* middle-high 0.0075*** 0.0027 0.0048*** 0.0014

Two conditions*highest 0.0037*** 0.0012 −0.0027** 0.0013

Three conditions *highest 0.0095*** 0.0012 −0.0026** 0.0013

Four conditions* highest 0.0113*** 0.0020 −0.0035** 0.0014

≥Five conditions* highest 0.0206*** 0.0028 −0.0019 0.0014

Number of medical conditions * ethnic concentration

One condition* lowest Reference Reference

Two conditions*middle-low −0.0006 0.0009 0.0011 0.0012

Three conditions * middle-low −0.0007 0.0013 0.0022* 0.0012

Number of medical conditions * ethnic concentration

Four conditions* middle-low −0.0020 0.0021 0.0012 0.0014

≥Five conditions* middle-low 0.0018 0.0029 0.0012 0.0013

Two conditions*middle 0.0004 0.0009 0.0006 0.0012

Three conditions * middle −0.0006 0.0013 0.0003 0.0012

Four conditions* middle −0.0034 0.0021 −0.0012 0.0014

≥Five conditions* middle 0.0016 0.0030 0.0004 0.0013

Two conditions*middle-high 0.0002 0.0009 0.0015 0.0012

Three conditions * middle-high −0.0013 0.0014 0.0021* 0.0013

Four conditions* middle-high −0.0056** 0.0022 0.0006 0.0014

≥Five conditions* middle-high −0.0056* 0.0030 0.0035** 0.0014

Two conditions*highest −0.0008 0.0012 0.0043*** 0.0012

Three conditions *highest −0.0021 0.0013 0.0047*** 0.0013

Four conditions* highest −0.0081*** 0.0021 0.0044*** 0.0013

≥Five conditions* highest −0.0070** 0.0030 0.0093*** 0.0013

Number of medical conditions * dependency quintile‡

One condition* lowest Reference Reference

Two conditions*middle-low 0.0016** 0.0007

Table 3 Continued

Continued

11Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

the financial burden of multimorbidity to the healthcare system is not simply equal to the sum of costs incurred by each individual condition. This non-linearity reflects the complex association of the degree of multimorbidity, the type of disease clusters and healthcare costs. It is likely that patients with multimorbidity might experience worse health outcomes and require more complex clin- ical management.9 They are also vulnerable to receiving redundant diagnostic tests,12 a suboptimal level of conti- nuity of care and inappropriate prescriptions,11 as current treatment guidelines are mainly focused on individual disease management.10 Thus, as the number of health- care providers involved in the patient’s care increases, information sharing and coordinating care across health- care providers may become increasingly challenging.39 Moreover, an increasing number of comorbid conditions may compromise patients’ ability to self-manage their diseases.40 Therefore, the high healthcare spending on multimorbidity found in our study underscores the need for ensuring continuity and coordination of care in this population.

More importantly, our study contributes to the under- standing of the association between the degree of multi- morbidity and healthcare costs. We observed that each unit increase in age amplified the rise in healthcare costs associated with an increasing number of medical condi- tions. The observed interaction effect may partly be due

to patterns in healthcare use among the older population, which is often characterised by polypharmacy and the use of continuing care services that are very costly. Addi- tionally, we found that the positive association between healthcare costs and levels of multimorbidity was stronger in men than in women among individuals <65 years. This sex difference might relate to the prevalence of different disease clusters in men and women, as men within this age group often experience life-threatening and more serious illnesses than women.41 42 For those >65 years, the increase in healthcare costs observed with the increase in the level of multimorbidity was significantly higher in women than men. This sex difference could be partially explained by longer life expectancy and greater risk of multimorbidity in older women than men,20 43 which may cause older women to be more dependent on formal (paid) healthcare services and other informal (unpaid) caregivers.

We observed small interaction effects of neighbour- hood-level socioeconomic characteristics on the asso- ciation between the number of medical conditions and healthcare costs. Living in lower income and marginalised areas, that is, areas with greater levels of instability, depen- dency or ethnic concentration, accelerated the increase in health system costs with increased multimorbidity. This may reflect a higher risk of experiencing more complex multimorbid conditions among individuals living in

<65 years (n=5 004 699)

≥65 years (n=1 634 390)

Coefficient SE Coefficient SE

Three conditions * middle-low 0.0018** 0.0010

Four conditions* middle-low 0.0004 0.0017

≥Five conditions* middle-low −0.0028 0.0026

Two conditions*middle 0.0015** 0.0001

Three conditions * middle 0.0030*** 0.0011

Four conditions* middle 0.0036** 0.0018

≥Five conditions* middle 0.0008 0.0025

Two conditions*middle-high 0.0017** 0.0008

Three conditions * middle-high 0.0029** 0.0012

Four conditions* middle-high 0.0028 0.0019

≥Five conditions* middle-high 0.0014 0.0027

Two conditions*highest 0.0018** 0.0009

Three conditions *highest 0.0032** 0.0013

Four conditions* highest 0.0041** 0.0020

≥Five conditions* highest 0.0038 0.0028

Akaike Information Criterion (AIC) 15,672,974 5,058,276

Bayesian Information Criterion (BIC) 15,674,535 5,059,515

***p<0.001, **p<0.05, *p<0.10. †Adjusted for primary care models and rurality index. ‡Interaction between the number of medical conditions and dependency quintile was not statistically significant and therefore excluded from a final model.

Table 3 Continued

12 Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

disadvantaged neighbourhoods,44 in turn leading to greater demand for and utilisation of healthcare. Another plausible explanation for this phenomenon is that indi- viduals living in more deprived areas may face barriers to accessing health services45 and therefore have delayed access to preventive healthcare interventions or treat- ments,46 consequently being at greater risk of developing poorer health outcomes and incurring higher healthcare costs. The effects of socioeconomic factors reported in this study should however be interpreted with caution, as they were derived based on neighbourhood. Although the interaction terms between socioeconomic factors and levels of multimorbidity were statistically significant, most of the estimated effect sizes were very small and may be a result of the large sample size used in this study.

strengths and limitations This population-based study was based on a large sample size and used robust costing and generalised linear model regression techniques. The availability of linked and patient-level health administrative databases allowed the estimation of the total health system costs associated with multimorbidity from all healthcare sectors, and the use of health administrative databases minimised potential recall and non-response biases that are commonly found in survey data.

Nonetheless, the results of this study should be inter- preted in light of the following limitations. First, we esti- mated healthcare costs based on 16 selected medical conditions, and this selection of a limited number of medical conditions is likely to underestimate the overall healthcare costs of multimorbidity. However, total cost estimates reported in our study were comprehensive, as they amounted to 86% of total allocatable government expenditures in Ontario in 2009.47Second, due to a paucity of data, certain costs (eg, deductibles and copay- ments borne by supplemental health insurance, out-of- pocket beneficiary payments and indirect costs associated with caregiving) were excluded from the analysis. In addi- tion, this study could not capture the costs of medications covered by private sectors, including private insurers and out-of-pocket expenses, which at the time of the study represented the largest component of total prescription drug costs of Canadians who are aged <65 years.48 For this reason, findings from this study may not be generalisable to other jurisdictions with different healthcare systems.

Third, this study did not take into account clusters of medical conditions. It is possible that the relationship between multimorbidity and healthcare costs may vary according to the type and patterns of comorbid medical conditions, which should be investigated in future studies. We chose to use disease counts in the present study, as there are no standards or guidelines for the definition or measurement of multimorbidity, and the choice of the measure would be subject to data avail- ability and the outcome of interest.49 50 A previous study conducted by our team5 has shown, however, that there was no common clustering of diseases among individuals

living with multimorbidity, as the number of disease clus- ters required to include 80% of the study population increased from 14 (among individuals with two condi- tions) to 2744 clusters of conditions (among individuals with five or more conditions), thus supporting the use of disease counts rather than clusters. Moreover, a previous systematic review showed that 132 definitions of multi- morbidity with 1631 criteria were used in the published literature.51 Our decision to use disease counts is also supported by a study by Islam et al52 indicating that the total number of chronic conditions were more predictive of out-of-pocket healthcare costs and high-cost users than disease clusters, dominant groups or dominant pairs.

COnClusiOn This population-based, retrospective cohort study high- lights the amount by which health system costs increased significantly with increasing levels of multimorbidity in a publicly financed healthcare system. The average and incremental healthcare costs reported in this study could serve as the foundation for future health economic eval- uation of interventions for preventing and managing multimorbidity. As the relationship between multimor- bidity and healthcare costs varies according to socio-de- mographic factors, interventions addressing disparities in healthcare in individuals living with multimorbidity may have the potential to reduce total health system costs.

Author affiliations 1Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada 2School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Canada 3Institute for Clinical Evaluative Sciences, Toronto, Canada 4Schools of Pharmacy, University of Waterloo, Ontario, Canada 5Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada 6Women’s College Research Institute, Women’s College Hospital, Toronto, Canada 7Department of Family Medicine, University of Alberta, Alberta, Canada 8Department of Health Sciences, Lakehead University, Thunder Bay, Canada 9Dalla Lana School of Public Health, University of Toronto, Toronto, Canada 10Toronto Rehabilitation Institute, Toronto, Canada

Contributors WPW was the lead for the conception and creation of the cohort. YB created the cohorts through data linkages and helped with data analysis and methods. KT and WW drafted the manuscript. KT, CM, AG, SB, AK, YB, YP and WPW interpreted the results and revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding This manuscript was supported through the Health System Performance Research Network (HSPRN) by a grant from the Ontario Ministry of Health and LongBTerm Care (MOHLTC grant #06034) and through provision of data by the Institute for Clinical and Evaluative Sciences with funding from an annual grant by the Ministry of Health and LongBTerm Care. The opinions, results and conclusions reported in this paper are those of the authors and are independent of the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or Ontario MOHLTC is intended or should be inferred. At the time this research was conducted, Dr Thavorn was partially supported by the HSPRN postBdoctoral award and the Li Ka Shing postBdoctoral award. None of the authors have any conflicts of interest to report.

Competing interests None declared.

ethics approval Research Ethics Board at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Provenance and peer review Not commissioned; externally peer reviewed.

13Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

reFerenCes 1. van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity

in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998;51:367–75.

2. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 2008;14(Suppl 1):28–32.

3. Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs. JAMA 1996;276:1473–9.

4. Schram MT, Frijters D, van de Lisdonk EH, et al. Setting and registry characteristics affect the prevalence and nature of multimorbidity in the elderly. J Clin Epidemiol 2008;61:1104–12.

5. Koné Pefoyo AJ, Bronskill SE, Gruneir A, et al. The increasing burden and complexity of multimorbidity. BMC Public Health 2015;15:415.

6. Marengoni A, von Strauss E, Rizzuto D, et al. The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. J Intern Med 2009;265:288–95.

7. Mondor L, Maxwell CJ, Bronskill SE, et al. The relative impact of chronic conditions and multimorbidity on health-related quality of life in Ontario long-stay home care clients. Qual Life Res 2016;25:2619–32.

8. St John PD, Tyas SL, Menec V, et al. Multimorbidity, disability, and mortality in community-dwelling older adults. Can Fam Physician 2014;60:e272–80.

9. Gijsen R, Hoeymans N, Schellevis FG, et al. Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001;54:661–74.

10. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716–24.

11. Caughey GE, Roughead EE, Vitry AI, et al. Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. Diabetes Res Clin Pract 2010;87:385–93.

12. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002;162:2269–76.

13. Bähler C, Huber CA, Brüngger B, et al. Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study. BMC Health Serv Res 2015;15:23.

14. Carstensen J, Andersson D, André M, et al. How does comorbidity influence healthcare costs? A population-based cross-sectional study of depression, back pain and osteoarthritis. BMJ Open 2012;2:e000809.

15. Zulman DM, Pal Chee C, Wagner TH, et al. Multimorbidity and healthcare utilisation among high-cost patients in the US Veterans Affairs Health Care System. BMJ Open 2015;5:e007771.

16. Jones AM, Rice N, dUva TB, et al. Modelling health care costs. Applied Health Economics. 2 ed. Routledge: Oxford, 2013.

17. Kadam UT, Uttley J, Jones PW, et al. Chronic disease multimorbidity transitions across healthcare interfaces and associated costs: a clinical-linkage database study. BMJ Open 2013;3:e003109.

18. Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20:125–44.

19. Rocca WA, Boyd CM, Grossardt BR, et al. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. Mayo Clin Proc 2014;89:1336–49.

20. Ornstein SM, Nietert PJ, Jenkins RG, et al. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J Am Board Fam Med 2013;26:518–24.

21. Canada H. Economic Burden of Illness in Canada. Ottawa: Health Canada, 1998.

22. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 2002;144:290–6.

23. Gershon AS, Wang C, Guan J, et al. Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J 2009;16:183–8.

24. Gershon AS, Wang C, Guan J, et al. Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD 2009;6:388–94.

25. Schultz SE, Rothwell DM, Chen Z, et al. Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 2013;33:160–6.

26. Hux JE, Ivis F, Flintoft V, et al. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512–6.

27. Guttmann A, Nakhla M, Henderson M, et al. Validation of a health administrative data algorithm for assessing the epidemiology of diabetes in Canadian children. Pediatr Diabetes 2010;11:122–8.

28. Tu K, Campbell NR, Chen ZL, et al. Accuracy of administrative databases in identifying patients with hypertension. Open Med 2007;1:e18–26.

29. Wodchis WP, Bushmeneva K, Nikitovic M, et al. Guidelines on Person-Level Costing Using Administrative Databases in Ontario Health System Performance Research Network (HSPRN). 2013.

30. Ontario Ministry of Health and Long Term Care. Schedule of benefits for physician services: consultations and visits. 2014 http://www. health. gov. on. ca/ english/ providers/ program/ ohip/ sob/ physserv/ a_ consul. pdf.

31. Canadian Institute for Health Information. CCRS Technical Document—Ontario RUG Weighted Patient Day. Ottawa: Canadian Institute for Health Information;, 2014.

32. Matheson FI, Dunn JR, Smith KL, et al. Development of the Canadian Marginalization Index: a new tool for the study of inequality. Can J Public Health 2012;103(8 Suppl 2):S12–16.

33. Matheson FI, White HL, Moineddin R, et al. Neighbourhood chronic stress and gender inequalities in hypertension among Canadian adults: a multilevel analysis. J Epidemiol Community Health 2010;64:705–13.

34. Nagl A, Witte J, Hodek JM, et al. Relationship between multimorbidity and direct healthcare costs in an advanced elderly population. Results of the PRISCUS trial. Z Gerontol Geriatr 2012;45:146–54.

35. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med 2007;22(Suppl 3):391–5.

36. Kralj B. Measuring Rurality - RIO2008_BASIC:Methodology and Results 2008. https://www. oma. org/ Resources/ Documents/ 2008RIO- FullTechnicalPaper. pdf.

37. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461–94.

38. Yoon J, Zulman D, Scott JY, et al. Costs associated with multimorbidity among VA patients. Med Care 2014;52:S31–S36.

39. Guthrie B, Saultz JW, Freeman GK, et al. Continuity of care matters. BMJ 2008;337:a867.

40. Kerr EA, Heisler M, Krein SL, et al. Beyond comorbidity counts: how do comorbidity type and severity influence diabetes patients' treatment priorities and self-management? J Gen Intern Med 2007;22:1635–40.

41. Macintyre S, Hunt K, Sweeting H. Gender differences in health: are things really as simple as they seem? Soc Sci Med 1996;42:617–24.

42. Rizza A, Kaplan V, Senn O, et al. Age- and gender-related prevalence of multimorbidity in primary care: the Swiss FIRE project. BMC Fam Pract 2012;13:113.

43. Abad-Díez JM, Calderón-Larrañaga A, Poncel-Falcó A, et al. Age and gender differences in the prevalence and patterns of multimorbidity in the older population. BMC Geriatr 2014;14:75.

44. Orueta JF, Nuño-Solinís R, García-Alvarez A, et al. Prevalence of multimorbidity according to the deprivation level among the elderly in the Basque Country. BMC Public Health 2013;13:918.

45. Williamson DL, Stewart MJ, Hayward K, et al. Low-income Canadians' experiences with health-related services: implications for health care reform. Health Policy 2006;76:106–21.

46. Crawford SM, Sauerzapf V, Haynes R, et al. Social and geographical factors affecting access to treatment of colorectal cancer: a cancer registry study. BMJ Open 2012;2:e000410.

47. Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. CMAJ 2016;188:182–8.

14 Thavorn K, et al. BMJ Open 2017;7:e017264. doi:10.1136/bmjopen-2017-017264

Open Access

48. Canadian Institute for Health Information. Prescribed Drug Spending in Canada, 2013: A Focus on Public Drug Programs. Ottawa: Canadian Institute for Health Information, 2014.

49. Stewart M, Fortin M, Britt HC, et al. Comparisons of multi- morbidity in family practice--issues and biases. Fam Pract 2013;30:473–80.

50. Diederichs C, Berger K, Bartels DB. The measurement of multiple chronic diseases--a systematic review on existing multimorbidity indices. J Gerontol A Biol Sci Med Sci 2011;66:301–11.

51. Le Reste JY, Nabbe P, Manceau B, et al. The European General Practice Research Network presents a comprehensive definition of multimorbidity in family medicine and long term care, following a systematic review of relevant literature. J Am Med Dir Assoc 2013;14:319–25.

52. Islam MM, Yen L, Valderas JM, et al. Out-of-pocket expenditure by Australian seniors with chronic disease: the effect of specific diseases and morbidity clusters. BMC Public Health 2014;14:1008.